Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia

Published:2016-07-29 Issue:4 Volume:175 Page:641-651
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chen Yixiang¹²,Germano Sandra¹²,Clements Chris¹²,Samuel Jesvin¹²,Shelmani Ghalia¹²,Jayne Sandrine²³,Dyer Martin J. S.²³,Macip Salvador¹²

Affiliation:

1. Mechanisms of Cancer and Ageing Laboratory; Department of Molecular and Cell Biology; University of Leicester; Leicester UK

2. Ernest and Helen Scott Haematological Research Institute; University of Leicester; Leicester UK

3. Department of Cancer Studies; University of Leicester; Leicester UK

Funder

Kay Kendall Leukaemia Fund

Pathological Society

Leicester Experimental Cancer Medicine Centre

Cancer Research UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14285/fullpdf

Reference62 articles.

1. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival;Alvi;Blood,2005

2. Emerging drug profile: cyclin-dependent kinase inhibitors;Blachly;Leukaemia & Lymphoma,2013

3. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia;Blachly;Seminars in Oncology,2016

4. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies;Bose;Expert Opinion on Investigational Drugs,2013

5. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;New England Journal of Medicine,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia;Frontiers in Pharmacology;2024-07-31

2. Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways;Toxicology in Vitro;2024-04

3. Prokaryotic expression of soluble IFN-λ1 recombinant protein with cold-shock system;Protein Expression and Purification;2024-03

4. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE;EXCLI J;2024

5. Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐X_L in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients;Molecular Oncology;2023-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3